MgCl or MgCl(2) (magnesium chloride) dosing, indications, interactions, adverse effects, and more , , , MgCl or MgCl(2) (magnesium chloride) dosing, indications, interactions, adverse effects, and more, , , , , , , , , , , , , , , , , Edition:EnglishFrançaisDeutsch, Search, , No Results, News & Perspective, Drugs & Diseases, CME & Education, Log In, Register, , , , , https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cDovL3JlZmVyZW5jZS5tZWRzY2FwZS5jb20vZHJ1Zy9tZ2NsLW9yLW1nY2wtMi1tYWduZXNpdW0tY2hsb3JpZGUtMzQ0NDQ2, , , processing.... , , , , , magnesium chloride (Rx)Brand and Other Names:MgCl or MgCl(2), Classes: Electrolytes, , Dosing & Uses, Interactions, Adverse Effects, Warnings, Pregnancy, Pharmacology, Administration, Images, Patient Handout, Formulary, Dosing & Uses, AdultPediatric, Dosage Forms & Strengths, , injectable solution, , 200mg/mL, , , tablet extended release, , 535mg (64mg elemental), , , more... RDA (Elemental Magnesium), , Males: 400-420 mg PO qDay, , 18-30 (Females) , , 310 mg PO qDay, , Pregnancy: 350 mg PO qDay, , Lactation: 310 mg PO qDay, , , >30 years (Females), , 320mg/day, , Pregnant women: 360 mg/day, , Lactating women: 320 mg/day, , , Hypomagnesemia, , 4 g (in 250 mL D5W) IV infusion; no more than 3 mL/min, , Usual Range: 1- 40 g IV qDay, , Use serum levels as guide to continue therapy, , Dosage Forms & Strengths, , injectable solution, , 200mg/mL, , , tablet extended release, , 535mg (64mg elemental), , , more... RDA, , <6 months: 30 mg/day, , 6-12 months: 75 mg/day, , 1-3 years: 80 mg/day, , 3-8 years: 130 mg/day, , 8-13 years: 240 mg/day, , 13-18 years: 410 mg/day (men); 360 mg/day (women); 400 mg/day (pregnant women); 360 mg/day (lactating women), , Interactions, Interaction Checker, magnesium chloride and , No Results, No Interactions Found, Interactions Found, Contraindicated, Serious - Use Alternative, Significant - Monitor Closely, Minor, Sort by : , , Adverse Effects, , Frequency Not Defined, , Respiratory depression, , Hypothermia, , Flushing, , Significant decrease in blood pressure, , Stupor, , Sweating, , , Warnings, , Contraindications, , Renal impairment, , Significant myocardial disease, , Comatose patients, , , Cautions, , Administer with caution if flushing & sweating occurs, , Keep Ca salt antidote for IV injection ready, , Risk of developing respiratory paralysis if long tendon reflux is not present, , Contains benzyl alcohol (toxic in children), , , Pregnancy & Lactation, , Pregnancy Category: C, , Lactation: Excreted in breast milk; use caution, , Pregnancy Categories, A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk. B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA:Information not available. more... Pharmacology, , Mechanism of Action, , Acts as cofactor in numerous enzymatic reactions involving protein synthesis and carbohydrate metabolism; depresses CNS, blocks peripheral neuromuscular transmission, produces anticonvulsant effects, , , Pharmacokinetics, , Distribution: 50-60% (Bone ); 1-2% (extracellular fluid), , Protein binding: 30% (albumin), , Excretion: Urine (as magnesium), , Absorption: Inversely proportional to amount ingested (15-36% at thigh doses and 40-60% at controlled dietary levels), , , Administration, , IV Preparation, , 4 g diluted in 250 mL D5W, , 10 g multidose vial, , , IV Administration, , NMT 3 mL/min, , , Images, , Patient Handout, Print w/ Office Info, Print w/out Office Info, , Formulary, FormularyPatient Discounts, To view formulary information first create a list of plans. Your list will be saved and can be edited at any time. Create Your List of Plans, Adding plans allows you to:, View the formulary and any restrictions for each plan. Manage and view all your plans together – even plans in different states. Compare formulary status to other drugs in the same class. Access your plan list on any device – mobile or desktop. The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information. View explanations for tiers and restrictions, Tier, Description, 1, This drug is available at the lowest co-pay. Most commonly, these are generic drugs. 2, This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs. 3, This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs. 4, This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products. 5, This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products. 6, This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products. NC, NOT COVERED, – Drugs that are not covered by the plan. Code, Definition, PA, Prior Authorization, Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription. , QL, Quantity Limits, Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered. , ST, Step Therapy, Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription. , OR, Other Restrictions, Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription. , Done, Add or Remove Plans, Plans for , Select State: , Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, , Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming, Non-Medicare PlansMedicare Plans, Select a box to add or remove a plan. close, Select a class to view formulary status for similar drugs, CLOSE, Additional Offers, CLOSE, Email to Patient, From:, To:, The recipient will receive more details and instructions to access this offer. By clicking send, you acknowledge that you have permission to email the recipient with this information. Send, CLOSE, Email Forms to Patient, From:,